Comparative Pharmacology
Head-to-head clinical analysis: GENTAMICIN SULFATE versus KANTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAMICIN SULFATE versus KANTREX.
GENTAMICIN SULFATE vs KANTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
1-2 mg/kg IV every 8 hours or 3-5 mg/kg IV every 24 hours for extended-interval dosing; typical duration 7-10 days.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 24-72 hours in renal impairment.
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Renal excretion of unchanged drug accounts for >90% of elimination; biliary/fecal <2%.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic